Clinical Development

 

 

AltaSeal® has been tested in First-in-Human clinical trials investigating its safety and effectivness, at European centres. In an outpatient procedure, AltaSeal® micro-inserts were placed in women without the need for general anaesthetic. 


In addition, the device has been shown to occlude fallopian tubes in women with hydrosalpinges who have had previous failed IVF therapy with excellent clinical results.


The development of AltaSeal® was reported in a peer reviewed journal, the article is titled Development and Initial Clinical Experience with AltaSeal®: A Novel Hysterscopically Placed Permanent Contraception System. The paper concludes that to date AltaSeal® can efficiently occlude fallopian tubes for both prevention of pregnancy and possibly return the rate of successful IVF treatments in women with hydrosalpinges to levels seen in patients without hydrosalpinges.

 

 

THIS DEVICE IS NOT YET FOR SALE IN THE UNITED STATES

– IT IS AN INVESTIGATIONAL DEVICE LIMITED BY FEDERAL (OR UNITED STATES) LAW TO INVESTIGATIONAL USE.